Is Zolpidem legal in South Africa?

Legal status

Controlled as a Specified Schedule 5 substance under the Medicines and Related Substances Act 101 of 1965, as at the SAHPRA consolidation of 1 August 2025; it is not printed in the Drugs and Drug Trafficking Act 140 of 1992.

Consequences if caught

Schedule 5 prints it under its own name as "Zolpidem" on page 177, on the line above Zopiclone, which carries no specified marker, and a few lines below Zaleplon, which carries none either; so of the three hypnotics of this kind only zolpidem is specified. The entry is followed by the double asterisk that paragraph c of the Schedule 5 preamble explains: "Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by" that mark. Section 22A (1) of the Medicines Act says no person shall "sell, have in his or her possession or manufacture any medicine, Scheduled substance, medical device or IVD, except in accordance with the prescribed conditions." Section 22A (16) (b) lets any person possess a Schedule 3, Schedule 4, Schedule 5 or Schedule 6 substance "if he or she is in possession of a prescription issued by an authorised prescriber", and section 22A (5) confines the sale of a Schedule 5 substance to a pharmacist acting on a prescription or on the verbal instructions of an authorised prescriber, to a manufacturer or wholesale dealer, and to the prescribing professions it lists. Section 22A (10) adds that no person shall sell or administer any Scheduled substance or medicine "for other than medicinal purposes". Section 29 (k) makes it an offence to contravene "any provision of section 22A", and section 30 (1) makes a person convicted of an offence referred to in section 29 "liable to a fine, or to imprisonment for a period not exceeding 10 years." Section 30 (2) lets the court declare the substance forfeited to the State, and section 30 (4) makes a magistrate's court competent to impose the penalty. Section 22A (11) (a) says no person shall import or export "any specified Schedule 5, Schedule 6, Schedule 7 or Schedule 8 substance" without a permit from the Director-General, and (11) (b) says such a permit "may be issued for any purpose other than the satisfaction or relief of a habit or craving". Under the Drugs Act the position is different. The single printed sedative of this receptor family is "Flunitrazepam." in Schedule 2 Part I. This substance is an imidazopyridine and not a benzodiazepine, so it has no diazepine ring and shares no more than a fused bicyclic nitrogen heterocycle with the printed entry. It does act at the same receptor. That leaves the row resting entirely on the second half of the homologue definition, with the first half unsatisfied, which is the same shape as the etizolam row but further away structurally. The Drugs Act limb that could still reach it is Part I paragraph 2 (c), "(c) all homologues of the listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance or exhibit pharmacodynamic properties similar to the listed substances in this Part of the Schedule), unless listed separately in any Part of Schedule 2." Parts II and III carry the same words as paragraph 2 (e). Because the printed relative sits in Part I, the scale that would follow is the Part I scale: use or possession under section 4 (a), an offence under section 13 (c) punishable under section 17 (b) by a fine, imprisonment for a period not exceeding five years, or both, and dealing under section 5 (a), an offence under section 13 (e) punishable under section 17 (c) by a fine, imprisonment for a period not exceeding 10 years, or both. The heavier scale, section 4 (b) with section 17 (d) and section 5 (b) with section 17 (e), at up to 15 and 25 years, applies only where the relative relied on is printed in Part II or Part III. If the limb does not reach the substance, the Drugs Act does not reach it at all. The Act supplies no test for deciding a homologue case. Capital exposure: none, and life exposure: none. Section 30 (1) of the Medicines Act fixes the penalty for an offence under section 29 at a fine or imprisonment for a period not exceeding 10 years, and section 17 sets out the whole penalty scale of the Drugs Act, whose highest figure is 25 years for dealing; neither Act carries a death sentence or a sentence of life imprisonment.

If prescribed or medical

Zolpidem is a medicine on prescription in South Africa. Outside the practitioners and pharmacies that section 22A (16) (c) and (d) cover, section 22A (16) (b) makes possession lawful only with a prescription issued by an authorised prescriber. For a visitor, SAHPRA's guideline SAHPGL-INSP-RC11, version 2 of June 2022, which restates the General Regulations, says "Any person entering the Republic may be in possession, for personal medicinal use, of- 3.2.1. a quantity of a Schedule 3, 4 or 5 substances, which shall not exceed for use for a period of six months; oral quantity of a Schedule 6 substance, which shall not exceed use for a period of 30 days;" and requires the original prescription, a certified copy of it, or a certificate or letter from the person who prescribed or dispensed it certifying the substance and quantity, with that person's name, physical and email address. The regulation the guideline restates sits behind the same SAHPRA sign in as the July 2026 schedules and was not itself read, so the allowance is stated here from the guideline. Section 22A (17) (a) defines an authorised prescriber as "a medical practitioner, dentist, veterinarian, practitioner, nurse or other person registered under the Health Professions Act, 1974". The guideline's own paragraph 3.1.3 says schedule 5, 6, 7 and 8 products "can only be imported with a permit issued in terms of Section 22A (9) and 22(A)(11)", in its part on commercial imports; nothing read says whether a traveller's personal supply within the allowance also needs that permit, and this cell does not decide it. Section 22A (6) (g) lets a Schedule 5 sale be repeated for no longer than six months, and then only if the prescriber has stated the number of times and the intervals, and section 22A (6) (h) (i) stops a Schedule 5 substance used for its anxiolytic, antidepressant or tranquillising properties being prescribed for longer than six months unless the prescriber has consulted a registered psychiatrist. The Drugs Act's own exceptions in section 4, paragraphs (i) to (vi), run through a practitioner acting in accordance with the Medicines Act, and section 2 of the Drugs Act says it applies "in addition to, and not in substitution for" the Medicines Act.

Documentation

Medicines Act search record, 3 October 2026. Terms searched: zolpidem, Stilnox, zopiclone and zaleplon. Zolpidem returns one Schedule 5 entry with the specified marker; zopiclone and zaleplon return Schedule 5 entries without it. The consolidation is a text PDF of 199 pages and was searched as extracted text, every schedule from 0 to 8. The Medicines Act schedules are stated as at the SAHPRA Consolidated Schedules of 1 August 2025, which on a comparison of two of its changes, the inserted fluconazole entry in Schedule 2 and the reworded nicotine metered spray line, both read on pages 4 and 6 of the scanned notice, already carry Government Notice R6466 of 1 August 2025; the rest of that notice was not read. That consolidation is read with Government Notice 7446 in Government Gazette 54627 of 8 May 2026, whose only change is to insert a veterinary yohimbine entry in Schedule 4; both were read on 3 October 2026. SAHPRA now labels the 1 August 2025 file an archived version and offers its July 2026 consolidation only through a Microsoft sign in that refused an anonymous request, so that file was not read, and this does not rule out a later amendment. The text of the Medicines Act read is the consolidation published in Government Gazette 40869 of 26 May 2017, whose list of amending Acts ends at Act 14 of 2015; a search on 3 October 2026 found no later amending Act, which does not rule one out. Drugs Act search record carried from the earlier cell. Search record. The terms searched were zolpidem, Stilnox, imidazopyridine, zopiclone and zaleplon. All five return zero occurrences, so the whole non-benzodiazepine hypnotic group is absent from the Act and not only this member of it. The text read for this cell is the Juta consolidation of the Act downloaded on 29 May 2025, taken from the Department of Justice copy at justice.gov.za whose sha256 begins bc1216a3. It carries the substitution of Schedules 1 and 2 by section 2 of Act 14 of 2022 with effect from 14 December 2022, and it marks section 7 of the Cannabis for Private Purposes Act 7 of 2024, the provision that would amend Schedule 2 again, as not yet put into operation by proclamation. The schedules are stated as at that consolidation and this does not rule out a later amendment made or commenced since.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with South Africa’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.